PF-06651600 + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alopecia Areata
Conditions
Alopecia Areata
Trial Timeline
Sep 15, 2020 → May 7, 2024
NCT ID
NCT04517864About PF-06651600 + Placebo
PF-06651600 + Placebo is a phase 2 stage product being developed by Pfizer for Alopecia Areata. The current trial status is terminated. This product is registered under clinical trial identifier NCT04517864. Target conditions include Alopecia Areata.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04517864 | Phase 2 | Terminated |
| NCT03232905 | Phase 1 | Completed |
Competing Products
20 competing products in Alopecia Areata
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Baricitinib | Eli Lilly | Phase 2 | 52 |
| CTP-543 | Sun Pharmaceutical | Phase 2/3 | 65 |
| CTP-543 | Sun Pharmaceutical | Phase 3 | 77 |
| Deuruxolitinib + Placebo | Sun Pharmaceutical | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 2/3 | 65 |
| Baricitinib 4 MG Oral Tablet | Eli Lilly | Approved | 85 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| minoxidil | Johnson & Johnson | Phase 3 | 77 |
| 5% Minoxidil + 2% Minoxidil | Johnson & Johnson | Phase 3 | 77 |
| Minoxidil + vehicle of 5% Minoxidil topical foam | Johnson & Johnson | Phase 2 | 52 |
| 5% Minoxidil Topical Foam + Vehicle Topical Foam | Johnson & Johnson | Phase 3 | 77 |
| Upadacitinib + Upadacitinib Placebo | AbbVie | Phase 3 | 77 |
| Upadacitinib + Placebo | AbbVie | Phase 3 | 77 |
| Secukinumab + Placebo | Novartis | Phase 2 | 52 |
| Daxdilimab | Amgen | Phase 2 | 51 |
| Ritlecitinib | Pfizer | Pre-clinical | 22 |
| LITFULO | Pfizer | Pre-clinical | 22 |
| Ritlecitinib | Pfizer | Pre-clinical | 22 |
| Ritlecitinib higher dose + Ritlecitinib lower dose + Placebo | Pfizer | Phase 3 | 76 |